CIRCULOGENE begins some tests with a patented methodologies resulting in enhanced dfDNA and cfRNA yields. By eliminating the need for a purification step, CIRCULOGENE overcomes the limitations associated with sample volume requirements. CIRCULOGENE preserves and extracts fragile cfRNA, enabling fusions and plasma PD-L1 to be effectively detected.
COMBINED NGS AND PCR METHODOLOGIES
CIRCULOGENE utilizes both NGS and PCR to provide a comprehensive and extensive marker portfolio resulting in accurate results. Rather than limiting the analytical process by only performing NGS, the addition of PCR enables other actionable markers found in RNA mutations and fusions. By combining NGS and PCR instrumentation, CIRCULOGENE provides the breadth of DNA menu and the depth for RNA detection.
The use of cfRNA preservation and PCR enables CIRCULOGENE to provide the only liquid biopsy method to include plasma PD-L1. CIRCULOGENE’s PD-L1 has also been demonstrated to providevaluable information in non-small cell lung cancer (NSCLC) immunotherapy patients.
The MSI Protocol is designed to provide physicians with a superior, functional, molecular measurement of the level of DNA mismatch repair deficiency demonstrated within their patient’s tumor. MSI-H (high) could be an indication of immunotherapy response in colorectal cancer.
Our personalized reports highlight the most significant actionable findings. CIRCULOGENE then provides referenced information on current FDA-approved treatment options that have proven effective for the tumor cfDNA and cfRNA mutations identified.